MedTrace Logo

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

NCT01499667 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2014-08-08

Study results available
· View outcomes & findings →

Summary

This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.

Conditions

  • Relapsing Remitting Multiple Sclerosis (RRMS)

Interventions

DRUG

Fingolimod

Fingolimod 0.5 mg capsules for oral administration once daily

DRUG

Placebo

Matching placebo in capsules for oral administration once daily.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Australia
  • Austria
  • Czechia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Israel
  • Italy
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01499667 on ClinicalTrials.gov